Autologous Dendritic Cell Vaccination in Multiple Myeloma Patients – A First Clinical Results and Safety Evaluation in a Phase II Clinical Trial
| Authors | |
|---|---|
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Six patients with multiple myeloma not requiring systemic therapy was enrolled to the study. Patients received 6 doses of dendritic cells (DCs)loaded with autologous Id-protein every 4 weeks. The vaccine was administred subcutaneously. Autologous mature DCs derived from peripherial blood monocytes were prepared in vitro and loaded with Id-protein under the GMP conditions. A clinical response was evaluated by measuring the monoclonal immunoglobulin levels in peripheral blood. An immune response was monitored by flow cytometry every 4 weeks as well as the production of interferon gamma (evaluated by Elispot) by myeloma-reactive T lymphocytes. A delayed type hypersensitivity test was performed every 3 months. Vaccination was well tolerated with only mild fever up to 37,5st.C in 1 patient, no other grade II-IV toxicities were observed. A local reaction (erythema or induration) was observed in all patients and disappeared in 2-6 days. The immune response to the vaccine was noticed in 3 of 4 patients who completed the vaccination and these 3 patients remained in stable disease while one evaluable patient with no immune response revealed progressive disease (the follow-up of these patients is 19-20 months, median 20 months). The trial is ongoing and a total number of 12 patients is planned to be enrolled. Vaccination with Id-protein loaded autologous DCs is a safe therapeutic strategy with no significant side effects. The final evaluation of clinical response needs to be performed in a longer follow-up. |
| Related projects: |